Navigation Links
Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
Date:12/8/2009

lly well tolerated in the study.(1) A small number of patients discontinued due to adverse events.(1)

"The impressive rates of response observed in this study, combined with the very low rate of disease progression seen in nilotinib-treated patients are very encouraging," said Professor Richard Clark, Consultant Haematologist at Royal Liverpool University Hospital and a trialist involved in this study. "Continued improvement in the treatment of Ph+ CML is very important and these results indicate that nilotinib may provide long-term improvement in progression-free survival."

95% of patients with CML have an abnormality known as the Philadelphia chromosome. This chromosome produces a type of protein called Bcr-Abl, which is responsible for the overproduction of the cancerous white blood cells that are the main feature in Ph+ CML.(3) Nilotinib is a potent and selective inhibitor of the Bcr-Abl protein, thereby inhibiting the production of these cancerous cells.(4,5)

"Novartis has been at the forefront of research on the molecular origin of Ph+ CML and this has led to the development of treatments with unprecedented effectiveness and safety," said Panos Alexakos, Oncology Business Unit Head for Novartis UK. "These data are exciting and the deeper molecular response demonstrated provides hope for further improvement in outcomes for patients with Ph+ CML in the future."

Novartis plans to file worldwide applications for approval of nilotinib as a treatment for adult patients with newly diagnosed Ph+ CML. Nilotinib is currently approved in more than 80 countries including the European Union (EU), United States and other countries for the treatment of adult patients with Ph+ CML in chronic phase or accelerated phase who are resistant or intolerant to prior treatment including imatinib.

Notes to editors

Study details

The clinical trial, Evaluating Nilot
'/>"/>

SOURCE Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Johnson & Johnson (NYSE: ... 10 a.m. (Eastern Time) on Thursday, April 23, 2015, from ... Investors and other interested parties may access ... Company,s website at www.jnj.com and clicking on the ... meeting will be made available a few hours after the ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... , March 26, 2015 "Whether it,s our ... one day." In a single sentence, ... scientific officer at Pfizer,s Centers for Therapeutic Innovation ... scientists fueling progress at America,s biopharmaceutical companies. ... side-by-side with academia, patient foundations and the National Institutes ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... publishes largest study comparing cancer risk of ezetimibe ... -BOSTON, March 25 A new study shows ... ezetimibe/simvastatin combination treatments, compared to cancer rates of ... conducted by Tufts Medical Center lipid and health ...
... N.J., March 25 DOR BioPharma, Inc. (OTC Bulletin ... company, announced today that it has entered into a ... with its clinical trials management partner, Numoda Corporation (Numoda). ... be completed in January 2010. This investment follows ...
Cached Medicine Technology:Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 2DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 3DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 4DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation 5
(Date:3/28/2015)... One in three young athletes who undergo ... at the American Orthopaedic Society for Sports Medicine’s ( ... term success of surgery for patients aged 18 years ... 242 patients who underwent ACL reconstruction between 1993 and ... from North Sydney Orthopaedic and Sports Medicine Centre. “Of ...
(Date:3/28/2015)... California (PRWEB) March 28, 2015 Andrew Hawley ... original 1960's Who psychedelic concert posters. The Who and the ... York on August 2, 1968. According to Hawley, “The Who ... many concert halls and college campuses. Perhaps the most famous ... with Jim Morrison and the Doors on August 2, 1968 ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Designers and ... new overlay entitled Scratches 5K from Pixel Film Studios. ... effects to any media inside Final Cut Pro X” ... Corporate saves time and is an effective tool for ... FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply drag ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... First Choice Emergency Room opened its new Summerwood ... W Lake Houston Pkwy, Houston, Texas and is open 24-7. ... to delivering the highest quality emergency medical care to my ... Choice Emergency Room Summerwood. , To celebrate the ... Creek High School at First Choice Emergency Room’s ribbon cutting ...
Breaking Medicine News(10 mins):Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2
... with rheumatoid arthritis (RA), the most common chronic ... individuals to experience depression. Although depression in primary ... examined whether rheumatologists and RA patients discuss depression ... the February issue of Arthritis Care & Research ...
... Key to Behavior Change & Decrease in ... Disparities in care of,diabetes patients in ... interventions, according to a new,study published in ... Rates of,glucose control testing among Latinos with ...
... Care and HealthEOS announced today that they have reached an agreement ... ... As a result of the settlement,agreement, WPS customers that use the ... facilities through the end of,2008. The services provided to these WPS ...
... Feb. 1 The Obesity Action,Coalition (OAC) is calling ... House Bill 282 (HB 282) that discriminates,against those affected ... The OAC strongly feels that HB 282 is outright ... often misguided attempts,proposed to address the obesity epidemic., ...
... Association (APHA) today released its annual congressional record,which measures ... to public health., APHA,s report was compiled by ... votes during the first session of the 110th,Congress in ... senators voted in support of APHA,s,position on all eight ...
... - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division ... retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein ... to severe plaque psoriasis following 12 weeks of treatment. ... greater in the ENBREL treated group compared to the ...
Cached Medicine News:Health News:Depression not discussed during rheumatoid arthritis doctor visits 2Health News:Lumetra Program Improves Diabetes Care Among Latinos 2Health News:Wisconsin Physicians Service Insurance Corporation, Aurora Health Care and HealthEOS Announce Settlement Agreement 2Health News:Obesity Action Coalition Calls on the State of Mississippi House of Representatives to Withdraw House Bill 282 Discriminating Against Those Affected by Obesity 2Health News:APHA Scores Members of Congress on Public Health Voting Record 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
... a scope designed specifically to enable direct ... also suitable for pediatric applications as well. ... a mere 2.8mm across. As a result, ... accomplished with greater ease. And since this ...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
... a double lumen tube made of silicone rubber ... ,Due to the characteristics of silicone rubber, Silbronco ... at insertion. Furthermore, the tube will not soften ... long term surgery., ,Silbronco is also especially ...
Medicine Products: